PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE Drug Patent Profile

« Back to Dashboard

When do Promethazine Hydrochloride And Phenylephrine Hydrochloride patents expire, and when can generic versions of Promethazine Hydrochloride And Phenylephrine Hydrochloride launch?

Promethazine Hydrochloride And Phenylephrine Hydrochloride is a drug marketed by Amneal Pharms and is included in one NDA.

The generic ingredient in PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE is phenylephrine hydrochloride; promethazine hydrochloride. Two suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride; promethazine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Promethazine Hydrochloride And Phenylephrine Hydrochloride

A generic version of PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE was approved as phenylephrine hydrochloride; promethazine hydrochloride by PAI HOLDINGS on December 7^th, 2006.

Summary for PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	040902-001	Aug 25, 2009	AA	RX	No	No

Investment Analysis of Promethazine Hydrochloride and Phenylephrine Hydrochloride

Last updated: February 22, 2026

Overview

Promethazine hydrochloride and phenylephrine hydrochloride are combined in formulations primarily to treat allergic conditions, cold symptoms, and nausea. Promethazine acts as an antihistamine, while phenylephrine functions as a decongestant. Their widespread use in over-the-counter (OTC) and prescription medications sustains steady demand, particularly in markets with high prevalence of allergic and respiratory illnesses.

Market Fundamentals

Market Size and Demand

• The global antihistamines market was valued at approximately USD 8.2 billion in 2022, expected to grow at a CAGR of 4.5% through 2030 [1].
• Decongestants, including phenylephrine, constitute a USD 1.2 billion segment within nasal spray and oral cold remedies, projected to expand at 3.8% annually [2].
• Promethazine’s usage spans prescription antiemetics and allergy therapies, with a global market size estimated at USD 0.9 billion in 2022.

Regulatory Environment

• Both drugs are classified as OTC in numerous markets, including the U.S.
• Regulatory concerns over phenylephrine’s efficacy in oral form led to scrutiny by the FDA, with recent reviews questioning its bioavailability [3].
• Promethazine requires prescription approval in many jurisdictions due to safety concerns, including sedation and potential for respiratory depression.

Pricing and Patent Status

• Both drugs are off-patent, with generic versions available.
• Wholesale acquisition costs (WAC) for combination tablets range from USD 0.05 to USD 0.15 per tablet, indicating low-cost manufacturing with sizable margins for generic manufacturers.

Competitive Landscape

Company	Market Share	Product Portfolio	R&D Focus
Teva Pharmaceuticals	25%	Multiple antihistamines and cold remedies	Generic development, bioequivalence studies
Sandoz	20%	OTC and prescription formulations	Bioavailability enhancement
Mylan	15%	Combination therapies	Nasal spray innovations
Others	40%	Various OTC and prescription brands	Niche formulations, biosimilars

Presence of multiple generic manufacturers increases price competition, limiting pricing power but ensuring sustained volume sales.

R&D and Innovation

• Limited R&D efforts target formulation improvements, such as sustained-release capsules.
• Clinical research mainly focuses on safety profiles, especially with promethazine’s sedative effects.
• Innovative delivery systems (e.g., nasal sprays for phenylephrine) aim to improve bioavailability and onset time, potentially creating premium formulations.

Market Risks and Opportunities

Risks

• Regulatory restrictions due to safety concerns, especially in pediatric populations.
• Efficacy debates surrounding phenylephrine's oral absorption diminish future growth prospects.
• Market saturation by low-cost generics constrains profit margins.

Opportunities

• Formulation innovations that address bioavailability issues.
• Expansion into emerging markets with rising allergy and upper respiratory disease prevalence.
• Development of combination products targeting multi-symptom relief and improved compliance.

Financial Outlook

• Revenue streams are primarily volume-driven.
• Margins are thin due to high generic competition but can be improved via formulation enhancements.
• Investment in bioavailability research and novel delivery platforms offers potential for differentiation.

Key Investment Considerations

• The drugs serve broad, ongoing demand in allergy and cold markets.
• Patent expiration and generic competition limit pricing power.
• Safety profile concerns influence regulatory and market access.
• Growth potential exists in emerging markets and through formulation innovations.

Key Takeaways

• The combination of promethazine hydrochloride and phenylephrine hydrochloride benefits from steady outpatient and OTC demand.
• Generic competition controls pricing; margins depend on manufacturing efficiency and formulation improvements.
• Regulatory scrutiny, especially for phenylephrine's efficacy and safety, influences market access.
• Innovation in delivery methods and bioavailability can create niche advantages.
• Emerging markets and product differentiation form critical avenues for growth.

FAQs

1. What are the main therapeutic uses of promethazine and phenylephrine?
   Promethazine is used for allergy relief, nausea, and insomnia. Phenylephrine primarily treats nasal congestion and cold symptoms.

2. How do regulatory agencies view phenylephrine’s effectiveness?
   The FDA has expressed concerns over phenylephrine's oral absorption efficacy, leading to reviews that could impact labeling and marketing.

3. What are the key risks for investors in these drugs?
   Safety concerns, regulatory challenges, and high generic competition limit profitability. Market saturation also depresses prices.

4. Are there ongoing R&D efforts for these drugs?
   R&D focuses mainly on formulation improvements, such as sustained-release versions and alternative delivery systems.

5. What markets offer growth opportunities?
   Emerging markets in Asia and Latin America, where allergy and cold remedies see rising demand, present substantial growth prospects.

References

[1] MarketsandMarkets. (2022). Antihistamines Market Analysis.
[2] Grand View Research. (2022). Decongestants Market Forecast.
[3] U.S. Food and Drug Administration. (2021). Review of Efficacy for Oral Phenylephrine.

---

End of analysis.